Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
Description
BACKGROUND: Monoclonal antibodies (mAbs) targeting the spike of SARS-CoV-2 prevent severe COVID-19. Omicron subvariants BQ.1.1 and XBB.1.5 evade neutralization of therapeutic mAbs, leading to recommendations against their use. Yet, the antiviral
